Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of docetaxel + oxaliplatin with or without fluoropyrimidine in previously untreated advanced gastric cancer
2005-005464-92Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in gastric cancer (GC) comparing Docetaxel + oxaliplatin, Docetaxel + oxaliplatin + 5-fluorouracil and Docetaxel + oxaliplatin + capecitabine (3 arms). Primary endpoint: Time to progression. Started Apr 2006; status: completed.
02
Drugs
docetaxeloxaliplatinfluorouracilcapecitabine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on 2005-005464-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005464-92.